Soligenix Receives Conditional FDA Acceptance of Proposed Brand Name HyBryte™ for SGX301 in CTCL
News provided by
Share this article
Share this article
PRINCETON, N.J., April 7, 2021 /PRNewswire/ Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today that the U.S. Food and Drug Administration (FDA) has conditionally accepted HyBryte™ as the proposed brand name for SGX301 (synthetic hypericin), the Company s novel first-in-class photodynamic therapy for first-line treatment of early stage cutaneous T-cell lymphoma (CTCL).
The name HyBryte™ was developed in compliance with the FDA s
PCG Digital: Soligenix Anticipated to Achieve Multiple Milestones in 2021
New York, New York (Newsfile Corp. - March 16, 2021) - PCG Digital The future is looking bright at Soligenix, Inc. In a corporate update released on February 24
th, Dr. Christopher Schaber, Chairman, President and CEO, updated investors on the status of ongoing research projects. The report suggests that multiple milestones will be achieved this year and next.
One of the key corporate highlights is the completion of a Phase 3 FLASH ( Fluorescent Light Activated Synthetic Hypericin ) study with SGX301 (synthetic hypericin), a treatment for cutaneous T-cell lymphoma (CTCL). Pending FDA clearance, the treatment will be marketed as HyBryte.
Cyclo Therapeutics Receives Positive Opinion from the Paediatric Committee of the European Medicines Agency on the Agreement of a Paediatric Investigation Plan for Trappsol Cyclo finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.
Global Phase 3 D-LIVR study enrollment completion planned in 2021
Peginterferon Lambda for HDV
Global Phase 3 LIMT-2 study initiation planned in 2021
Zokinvy™ (lonafarnib) for Progeria and Processing-Deficient Progeroid Laminopathies
U.S. commercial launch in January 2021
EMA decision expected in 2H21
Lambda for COVID-19
Lancet Respiratory Medicine (Feld et al, 2021)
Considering strategic options to advance program
Avexitide for Post-Bariatric Hypoglycemia (PBH)
Positive Phase 2 PREVENT study published in
JCEM (Craig et al, 2021)
Corporate
Pro-forma cash, cash equivalents and investments of $176.2M, including $128.8M as of December 31, 2020 plus $47.4M from net PRV sale proceeds received in January 2021, expected to fund planned operations through Q4 2023
Fourth Quarter and Full Year 2020 Financial Results
Eiger BioPharmaceuticals Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Business Update
- Phase 3 HDV D-LIVR (Lonafarnib) to Complete Enrollment in 2021
- Phase 3 HDV LIMT-2 (Lambda) to Initiate in 2021
- Strong Cash Position with $176 Million Pro-Forma Cash to Begin 2021
News provided by
Share this article
Share this article
PALO ALTO, Calif., March 9, 2021 /PRNewswire/ Eiger BioPharmaceuticals, Inc. (Nasdaq: EIGR), a commercial-stage biopharmaceutical stage company focused on the development and commercialization of foundational therapies for Hepatitis Delta Virus (HDV) infection, today reported financial results for fourth quarter and full year 2020 and provided a business update. In 2021, we plan to achieve important, value creating milestones in both of our HDV clinical programs, said David Cory, President and CEO of Eiger. We will complete enrollment of the Phase 3 D-LIVR study of Lonafarnib, the first and only oral agent in development